RESONO OPHTHALMIC has just participated to the ARVO 2021 Annual Meeting with a presentation about the latest clinical trial, carried out by Drs Alexandra Trivli, Georgios Dalianis, Chryssa Terzidou from the Department Of Ophthalmology, Konstantopouleio General Hospital, Athens, Greece.

The trial investigated the efficacy of the low-power, high-frequency electrical current treatment administered by Rexon-Eye® in a cohort of 18 patients affected by mixed-type dry eye disease (DED) of medium to severe level.

The lecture Improvement in mixed-type dry eye patients after treatment with the QMR®-based electrotherapy device Rexon-Eye® was presented by Alfredo Ruggeri, President & CEO Resono Ophthalmic, and led to the following conclusion:

In accordance with previous studies, Rexon-Eye® proved to be very effective in improving subjective and objective ocular parameters. Of particular interest in this mixed-type DED patients cohort is the capability of Rexon-Eye® to normalize the clinical parameters affected by inflammation.

For more details, please see the abstract and watch the recording of ARVO Presentation.